Patients were randomly assigned to orforglipron (12 mg or 36 mg) or semaglutide (7 mg or 14 mg) with a treatment period of 52 weeks, from 22 September 2022 to 22 August 2025, and drugs were administered orally once per day
Not as powerful as tirzepatide or retatrutide in head-to-head data
Takeaway: When appetite is suppressed by GLP-1 medications, hitting protein targets requires deliberate planning and often supplementation
Further research is needed to elucidate the precise mechanisms through which GLP-1R agonists exert their benefits and to establish their long-term safety and efficacy in diverse HFpEF populations
Alternatives to glutathione supplements From our research, we've identified two viable alternatives to glutathione supplementation
Remember that some lab-to-lab variability occurs due to differences in equipment, techniques, and chemicals used